Skip to main content

Newsroom press releases

13/10/26 - 13:00

Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
Products Immunodiagnostic
Download

02/10/26 - 14:22

Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
Other
Download

31/07/26 - 12:50

Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
Financial Data
Download

19/06/26 - 15:45

Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
Products Molecular
Download

20/05/26 - 11:16

Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
Financial Data
Download

19/05/26 - 19:23

Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
Products Molecular
Download

08/05/26 - 17:54

Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
Financial Data
Download

04/05/26 - 17:45

Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
Other
Download

29/04/26 - 15:52

Shareholders' Meeting 2026 (166.06 KB)
Other
Download

07/04/26 - 10:05

Communication on total amount of voting rights (7 April 2026) (225.44 KB)
Other
Download

25/03/26 - 12:04

Publication of the document for the Ordinary Shareholders' Meeting scheduled on April 29, 2026 (181.97 KB)
Financial Disclosures
Download

20/03/26 - 17:44

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
Financial Data
Download

19/03/26 - 9:47

Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
Other
Download

24/02/26 - 7:06

Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
Products Immunodiagnostic
Download

03/02/26 - 12:13

Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
Products Molecular
Download

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic
Download

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other
Download

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular
Download

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other
Download

19/12/16 - 10:00

Co-optation of a Director (333.18 KB)
Financial Data
Download

10/11/16 - 1:00

DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
Financial Data
Download

02/11/16 - 1:00

DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
Products Molecular
Download

30/08/16 - 2:00

DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)
Acquisition / Partnership
Download

22/08/16 - 2:00

DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
Products Immunodiagnostic
Download

04/08/16 - 2:00

The Board of Directors approves results for H1'16 (697.16 KB)
Financial Data
Download

28/07/16 - 2:00

DiaSorin starts selling Vitamin D in Japan (724.4 KB)
Products Immunodiagnostic
Download

14/07/16 - 2:00

DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
Products Molecular
Download

10/06/16 - 2:00

Weekly report treasury shares buy-back (289.83 KB)
Financial Data
Download

10/06/16 - 2:00

Conclusion buy-back plan (367.77 KB)
Financial Data
Download

07/06/16 - 2:00

DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
Products Immunodiagnostic
Download

03/06/16 - 2:00

Weekly report treasury shares buy-back (290.21 KB)
Financial Data
Download

30/05/16 - 2:00

Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
Financial Data
Download

27/05/16 - 2:00

Weekly report treasury shares buy-back (289.34 KB)
Financial Data
Download

20/05/16 - 2:00

Weekly report treasury shares buy-back (290.09 KB)
Financial Data
Download

13/05/16 - 2:00

Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)
Acquisition / Partnership
Download

12/05/16 - 2:00

Start up treasury shares buy-back plan (305.9 KB)
Financial Data
Download

09/05/16 - 2:00

The Board of Directors approves the results for Q1'16 (632.78 KB)
Financial Data
Download

28/04/16 - 2:00

Shareholders' Meeting FY 2015 (365.15 KB)
Financial Data
Download

30/03/16 - 2:00

DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)
Acquisition / Partnership
Download

09/03/16 - 1:00

The Board of Directors approves the results for FY'15 (785.08 KB)
Financial Data
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.